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ABSTRACT 
 
 
The impact of translationally controlled tumor protein  
on the podocyte hypertrophy under diabetic conditions 
 
 
Dong Ki Kim 
 
Department of Medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Shin-Wook Kang) 
 
Background: Hypertrophic mechanism requires cell cycle arrest at the G1/S 
interphase, which is principally mediated by inhibitors of cyclin-dependent 
kinase (CDK), namely CDK-inhibitors (CKIs). In addition to CKIs, recent 
studies have shown that activation of mRNA translation regulating signaling 
pathways such as mammalian target of rapamycin (mTOR) is also implicated 
in cellular hypertrophy in various diseases. Translationally controlled tumor 
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protein (TCTP) is highly conserved in eukaryotic cells and has been suggested 
to be involved in various intracellular processes including cell proliferation 
and growth by regulating mRNA translation pathway. Since glomerular cells 
hypertrophy is a characteristic finding in diabetic nephropathy, there is a 
possibility that TCTP may play an important role in the pathogenesis of 
diabetic nephropathy. However, the functional role of TCTP on cellular 
hypertrophy under diabetic conditions has never been explored. In this study, I 
examined not only the changes in TCTP expression in high glucose-stimulated 
podocytes and in experimental diabetic glomeruli but also the impact of TCTP 
on podocyte hypertrophy under diabetic conditions. 
Methods: In vitro, immortalized mouse podocytes ether with or without 
transfection of TCTP shRNA expressing lentivirus were serum restricted for 
24 hr, after which the medium was changed to RPMI medium containing 5.6 
mM glucose (NG), NG+24.4 mM mannitol (NG+M), NG+10-6 M angiotensin 
II (NG+ANG II), 30 mM glucose (HG), or HG+10-7 M L-158,809 (HG+ARB). 
In vivo, 32 C57BL/6 mice were injected either with diluent (n=16, C) or 
streptozotocin intraperitoneally for 5 consecutive days (n=16, DM). Eight 
mice from each group were treated with lentivirus containing TCTP shRNA 
(LV-shTCTP). Real-time PCR for TCTP mRNA expression and Western 
blotting for TCTP, phospho-4EBP1, 4EBP1, phospho-p70S6K, p70S6K, p27, 
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p21 or β-actin protein expression were performed with cell lysates and sieved 
glomeruli. Double immunofluorescence (IF) staining with synaptopodin and 
TCTP was also performed with renal tissue. Podocyte hypertrophy was 
assessed by measurement of cellular protein/cell counts and by flow 
cytometry, and glomerular volume by morphometry. 
Results: Compared to NG cells, TCTP mRNA and protein expression were 
significantly increased in podocytes exposed to HG for 48 hrs, and this 
increase in TCTP expression was abrogated by ARB treatment. Similarly, 
ANG II induced TCTP mRNA and protein expression in cultured podocytes. 
Glomerular TCTP expression was also significantly higher in DM compared 
with C mice. Double IF staining for TCTP and synaptopodin revealed that 
podocytes were the main cells responsible for the increase in TCTP protein 
expression under diabetic conditions. TCTP inhibition using LV-shTCTP 
ameliorated the increase in phospho-4EBP1, phospho-p70S6K, and p27 
protein expression in high glucose-stimulated podocytes and in diabetic 
glomeruli along with reduced podocyte and glomerular size. 
Conclusion: I demonstrate for the first time that TCTP expression is 
increased in podocytes under diabetic conditions and that inhibition of TCTP 
attenuates the activation of mTOR target molecules, 4EBP1 and p70S6K, and 
CKIs expression, along with reduced podocyte and glomerular size. These 
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findings suggest that TCTP may play an important role in the process of 
podocyte hypertrophy under diabetic conditions via regulating mRNA 
translation and inducing cell cycle arrest at the G1/S interphase. 
 
______________________________________________________________ 
Key words: translationally controlled tumor protein, diabetic nephropathy, 
podocyte, hypertrophy 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
  
The impact of translationally controlled tumor protein 
on the podocyte hypertrophy under diabetic conditions 
 
Dong Ki Kim 
 
Department of Medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Shin-Wook Kang) 
 
 
I. INTRODUCTION 
 
Diabetic nephropathy, the leading cause of end-stage renal disease in many 
countries, is characterized by renal hypertrophy in the early course of the 
disease1, which is mainly due to glomerular and tubular hypertrophy, 
accumulation of extracellular matrix, and hemodynamic alterations2. Among 
these, glomerular hypertrophy is partly contributed by glomerular cells 
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hypertrophy, and recent studies have suggested that interruption of glomerular 
hypertrophy may ameliorate the chronic changes of diabetic nephropathy3, 
suggesting that understanding the pathogenetic mechanism of cellular 
hypertrophy under diabetic conditions is important and can be applied to the 
prevention and treatment of diabetic nephropathy4. While the diabetic milieu 
per se, hemodynamic changes, and local growth factors such as angiotensin II 
(ANG II) are considered to be mediators in the pathogenesis of glomerular 
cells hypertrophy5, the underlying pathways mediating these processes are not 
well understood. 
Cell culture experiments using mesangial cells and podocytes under high 
glucose conditions and in vivo studies in various models of diabetes suggest 
the hypertrophic mechanism requires the combined effect of mitogen-induced 
entry into the cell cycle and subsequent arrest at the G1/S interphase5-8. 
Numerous studies have demonstrated this cell cycle arrest is principally 
mediated by inhibitors of cyclin-dependent kinase (CDK), namely CDK-
inhibitors (CKIs), which are classified into two groups according to their 
structural homology: the INK family (p15, p16, p18, and p19) and the 
Cip/Kip family (p21, p27, and p57)9,10. 
In addition to CKIs, activation of mRNA translation regulating signaling 
pathways including phosphatidylinositol-3 (PI3) kinase/Akt/mammalian 
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target of rapamycin (mTOR), the AMP-activated protein kinase 
(AMPK)/tuberous sclerosis complex (TSC) 1/TSC 2/Ras homologue enriched 
in brain (Rheb), and the extracellular signal-regulated kinase (ERK) 1/2 
signaling pathway have been found to contribute to glomerular hypertrophy in 
animal model of diabetes11-16. These pathways are closely linked with one 
another and eventually promote the initiation and elongation phase of mRNA 
translation, resulting in increased cell size14-16. Among these pathways, mTOR 
and its downstream effectors such as eukaryotic elongation factor 4E binding 
protein 1 (4EBP1) and p70 S6 ribosomal protein kinase (p70S6K) have shown 
to play a pivotal role in the hypertrophic process under diabetic conditions14-17. 
Since MacDonald et al18 first identified translationally controlled tumor 
protein (TCTP) as a stimulus of histamine release from human basophils, it 
has been believed to play an important role in the chronic allergic disease 
process. Recently, however, many studies have demonstrated that TCTP has 
multifunctional intracellular functions, including cell proliferation, growth, 
survival, and stress responses19, in addition to its original histamine releasing 
function. Even though the precise mechanisms of TCTP on the regulation of 
cell growth and proliferation remain elusive, recent investigations have 
revealed that TCTP directly interact with eukaryotic elongation factor (eEF) 
1A, subsequently rendering more efficient elongation phase of mRNA 
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translation20. Moreover, TCTP is reported to activate PI3 kinase/Akt and 
Ras/Raf/ERK pathway and to directly regulate Rheb, which is considered a 
upstream regulator of mTOR/S6K/4EBP signaling, suggesting that TCTP may 
not only play a key physiological role in cell survival but also induce cellular 
or organ hypertrophy through the phosphorylation of the effectors of mRNA 
translation such as 4EBP1 and p70S6K21-23. 
Since glomerular cell hypertrophy is a characteristic finding in diabetic 
nephropathy, there is a possibility that TCTP may play an important role in the 
pathogenesis of cellular hypertrophy through the activation of mRNA 
translation. However, the functional role of TCTP under diabetic conditions 
has never been explored. In this study, I examined not only the changes of 
TCTP expression in podocytes under diabetic conditions but also the impact 
of TCTP on podocyte hypertrophy. In addition, the signaling pathway 
regulating podocyte hypertrophy was also investigated. 
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II. MATERIALS AND METHODS 
 
1. Generation of TCTP shRNA expressing lentivirus 
The cDNA sequence of the mouse TCTP (GenBank accession number, 
NM009429) was examined using computer software to select appropriate 
siRNA target sites (http://jura.wi.mit.edu/bioc/siRNAext/home.php). Three 
pairs of oligonucleotides corresponding to TCTP cDNA positions 34~54 bp, 
178~198 bp, and 447~467 bp were designed. A Blast search of these 
sequences confirmed their specificity to TCTP only. In addition, a scrambled 
sequence with no near match to any known sequence was designed as control. 
Each oligonucleotide was composed of a 21-nucleotide sense sequence, a loop, 
a 21-nucleotide antisense sequence, five thymidines as well as overhang 
sequences CGA at the 5′ and TTT at the 3′ for cloning purposes (Table. 1). 
The pairs of corresponding designed oligonucleotides were annealed and 
inserted between the BstBI and BbsI sites of the pCMV-U6 plasmid (Gift from 
Dr. Pavel Osten, Feinberg School of Medicine, IL, USA)24. Positive clones 
were identified by PCR using the sense primer (5’-CCC GCT AGC ATC CGA 
CGC CGC CAT CTC TA-3’) and the antisense primer (5’-CCA CCG CAT 
CCC CAG CAT GCC -3’) under the following conditions: 30 cycles of 
denaturation at 94°C for 45 sec, annealing at 60°C for 45 sec, and extension at 
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72°C for 45 sec. Initial heating at 94°C for 9 min and final extension at 72°C 
for 7 min were performed for all PCRs. The PCR products were analyzed by 
electrophoresis in a 2.0% agarose gel, and the positive samples were 
sequenced, and named as pCMV-U6-TCTP shRNA-1, -2, -3, and -scrambled. 
The U6-TCTP shRNA cassettes were recloned into lentiviral transfer 
vector FUGW (Gift from by Dr. Pavel Osten)25 using NheI/BstBI, and as a 
result, a vector FUG-TCTP shRNA was created.  
TCTP construct was also generated by PCR from mouse genomic DNA 
with primers 5’-A ACC GCT AGA TCT ATG ATC ATC TAC CGG GAC 
ATA-3’ and 5’-AGG CCG GTC GAC TTA ACA TTT CTC CAT CTC TAA 
GCC-3’, and cloned into pEGFP-C1 (BD Biosciences Clontech, Franklin 
Lakes, NJ, USA) using BglII/SalI, resulting in a vector pEGFP-C1-TCTP. 
Lentiviruses were produced as previously described26. Human embryonic 
kidney (HEK) 293FT cells (Invitrogen, Carlsbad, CA, USA) were transfected 
by using the calcium phosphate method with the expression and two helpers, 
packaging plasmid pCMV Δ8.9 and vesicular stomatitis virus G protein 
plasmids at 1, 7.5, and 5.5 μg of DNA per 100 mm plate. After 48 hr, the 
supernatants of four plates were pooled, spun at 780 g for 5 min, and filtered 
at a 0.45 μm pore size. Next, a centrifugation at 83,000 g for 1.5 hr was 
performed, and the pellet was resuspended in 100 μl of phosphate-buffered 
10 
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saline (PBS). Titers of lentivirus were determined by transfecting HEK 293T 
cell with a dilution series of viral suspension, and the lentivirus with a titer of 
4 × 108 transfection units/ml was stored at -80°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Sequences of TCTP shRNAs and TCTP shRNA-scrambled 
  Sense Loop Antisense 
TCTP shRNA-1 
Forward : TTT GAGCTGTTCTCCGACATCTAC GTGAAGCCACAGATG GTAGATGTCGGAGAACAGCTC 
Reward:  CGAAAAA GAGCTGTTCTCCGACATCTAC CATCTGTGGCTTCAC GTAGATGTCGGAGAACAGCT 
TCTP shRNA-2 
Forward:  TTT GAAGGTACCGAAAGCACAGTA GTGAAGCCACAGATG TACTGTGCTTTCGGTACCTTC 
Reward:  CGAAAAA GAAGGTACCGAAAGCACAGTA CATCTGTGGCTTCAC TACTGTGCTTTCGGTACCTT 
TCTP shRNA-3 
Forward: TTT GGACTACCGTGAAGATGGTGT GTGAAGCCACAGATG ACACCATCTTCACGGTAGTCC 
Reward: CGAAAAA GGACTACCGTGAAGATGGTGT CATCTGTGGCTTCAC ACACCATCTTCACGGTAGTCC 
TCTP shRNA-scrambled 
Forward: TTT GCGTATGAGTAGTGCGCAGAT GTGAAGCCACAGATG ATCTGCGCACTACTCATACGC 
Reward: CGAAAAA GCGTATGAGTAGTGCGCAGAT CATCTGTGGCTTCAC ATCTGCGCACTACTCATACGC 
 
12 
 
2. Podocyte culture 
Conditionally immortalized mouse podocytes were kindly provided by Dr. 
Peter Mundel (University of Miami Miller School of Medicine, Miami, 
Florida, USA) and were cultured as previously described27. Briefly, frozen 
podocytes were first grown under permissive conditions at 33°C in RPMI 
1640 media containing 10% fetal bovine serum, 50 U/ml γ-interferon and 100 
U/ml of penicillin/ streptomycin in collagen coated flasks, and the γ-interferon 
tapered down to 10 U/ml in successive passages. Cells were then trypsinized 
and subcultured in six-well plates without γ-interferon (non-permissive 
conditions) and allowed to differentiate at 37°C with media changed on 
alternate days. Differentiation of podocytes grown for 10 days at 37°C was 
confirmed by the identification of synaptopodin, a podocyte differentiation 
marker, by RT-PCR and Western blotting (data not shown). In case of 
lentiviral transfection to podocytes, 1 ml of the lentivirus suspension was 
added to the wells after the confirmation of differentiation. 
Lentiviral transfected or non-transfected podocytes were serum restricted 
for 24 hr, after which the medium was changed to RPMI medium containing 
normal glucose (NG) (5.6 mM glucose), NG+24.4 mmol mannitol, NG+10-6 
M/L ANG II (NG+ANG II), high glucose (HG) (30 mM glucose), HG+10-7 
M/L L-158,809, a selective ANG II type I receptor blocker (HG+ARB). After 
13 
 
48 hr, cells were harvested for either RNA or protein. 
 
3. Animals 
All animal studies were conducted using approved protocols. C57BL/6 
mice weighing 18~22 g were injected either with diluent [n=16, Control (C)] 
or with 55 mg/kg/day streptozotocin (STZ) intraperitoneally for 5 
consecutive days [n=16, Diabetes (DM)]. Diabetes was confirmed by tail 
vein blood glucose levels above 300 mg/dl on the third day after the last STZ 
injection. After the confirmation of diabetes, eight mice from each group 
were treated with lentivirus vector containing TCTP shRNA at a dose of 4 × 
108 transfection units on day 0 and 7. Mice were housed in a temperature-
controlled room and were given free access to water and standard laboratory 
chow during the 6-week study period.  
Body weights were checked biweekly, and kidney weights were 
measured at the time of sacrifice. Serum glucose and 24-hr urinary albumin 
were measured weekly and at the time of sacrifice, respectively. Blood 
glucose was measured by glucometer and 24-hr urinary albumin excretion 
by enzyme-linked immunosorbent assay (ELISA) (Albuwell M, Exocell, Inc., 
Philadelphia, PA, USA). 
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4. Glomerular isolation 
Glomeruli were isolated by sieving technique as previously described28. 
Purity of the glomerular preparation was greater than 98% as determined by 
light microscopy. 
 
5. Total RNA isolation 
Podocytes RNA from each plate was extracted as previously described29. 
Briefly, after cell scraping with 800 μl of RNA STAT-60 reagent (Tel-Test, 
Inc., Friendswood, TX, USA), the mixture was vortexed and stored for 5 
minutes at room temperature. Next, 160 μl of chloroform was added and the 
mixture was shaken vigorously for 30 sec. After 3 min, the mixture was 
centrifuged at 12,000 g for 15 min at 4°C and the upper aqueous phase 
containing the extracted RNA was transferred to a new tube. RNA was 
precipitated from the aqueous phase by 400 μl isopropanol and pelleted with 
centrifugation at 12,000 g for 30 min at 4°C. The RNA precipitate was 
washed with 70% ice-cold ethanol, dried using Speed Vac, and dissolved in 
DEPC-treated distilled water. Total RNA from sieved glomeruli was 
extracted similarly. Podocyte and glomerular RNA yield and quality were 
assessed based on spectrophotometric measurements at the wavelength of 
260 and 280 nm. 
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 6. Reverse transcription 
First strand cDNA was made by using a Boehringer Mannheim cDNA 
synthesis kit (Boehringer Mannheim GmbH, Mannheim, Germany). Two μg 
of total RNA extracted from cultured podocytes and sieved glomeruli were 
reversely transcribed using 10 μM random hexanucleotide primer, 1 mM 
dNTP, 8 mM MgCl2, 30 mM KCl, 50 mM Tris-HCl, pH 8.5, 0.2 mM 
dithiothreithol, 25 U RNAse inhibitor, and 40 U AMV reverse transcriptase. 
The mixture was incubated at 30°C for 10 min and 42°C for 1 hr followed 
by inactivation of the enzyme at 99°C for 5 min. 
 
7. Real-time PCR 
The primers used for TCTP and 18s amplifications were as follows: 
TCTP sense 5’- GCT AGG ACA GTT ATA AGC TCA GGC -3’, antisense 
5’- TCC TGGTGT TGT ATG GAT GG -3’; and 18s sense, 5’-AGT CCC 
TGC CCT TTG TAC ACA-3’, antisense 5’-GAT CCG AGG GCC TCA CTA 
AAC-3’. Using the ABI PRISM® 7700 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA), the PCR was performed with a total 
volume of 20 μl in each well, containing 10 μl of SYBR Green® PCR Master 
Mix (Applied Biosystems), 5 μl of cDNA corresponding to 25 ng of RNA, 
16 
 
and 5 pmol sense and antisense primers. Primer concentrations were 
determined by preliminary experiments that analyzed the optimal 
concentrations of each primer. Each sample was run in triplicate in separate 
tubes to permit quantification of the TCTP gene normalized to the 18s gene. 
The PCR conditions were as follows: for TCTP, 38 cycles of denaturation at 
95°C for 30 sec, annealing at 58°C for 30 sec, and extension at 72°C for 1 
min; and for 18s, 35 cycles of denaturation at 94.5°C for 30 sec, annealing at 
60°C for 30 sec, and extension at 72°C for 1 min. An initial heating at 95°C 
for 9 min and a final extension at 72°C for 7 min were performed for all 
PCRs. After real-time PCR, the temperature was increased from 60 to 95°C 
at a rate of 2°C/min to construct a melting curve. A control without cDNA 
was run in parallel with each assay. The cDNA content of each specimen was 
determined using a comparative CT method with 2-∆∆CT. The results are given 
as relative expression normalized to the 18s gene and expressed in arbitrary 
units. Signals from C glomeruli and NG cells were assigned a relative value 
of 1.0. In pilot experiments, PCR products run on agarose gels revealed a 
single band on agarose gels. 
 
8. Western blot analysis 
Podocytes harvested from plates and sieved glomeruli were lysed in 
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sodium dodecyl sulfate (SDS) sample buffer (2% sodium dodecyl sulfate, 10 
mM Tris-HCl, pH 6.8, 10% [vol/vol] glycerol). Lysate was centrifuged at 
10,000 g for 10 min at 4°C, and the supernatant was stored at -70°C until all 
mice were sacrificed. Protein concentrations were determined with a Bio-Rad 
kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Aliquots of 50 μg 
proteins were treated with Laemmli sample buffer, heated at 100°C for 5 min, 
and electrophoresed in 8% or 12% acrylamide denaturing SDS 
polyacrylamide gel. Proteins were transferred to Hybond-ECL membrane 
(Amersham Life Science, Inc., Arlington Heights, IL, USA) using a Hoeffer 
semidry blotting apparatus (Hoeffer Instruments, San Francisco, CA, USA), 
and the membrane was then incubated in blocking buffer A (1 × PBS, 0.1% 
Tween-20, and 8% non-fat milk) for 1 hr at room temperature, followed by an 
overnight incubation at 4°C in a 1:1000 dilution of monoclonal antibody to 
TCTP (MBL International, Inc., Woburn, MA, USA), polyclonal antibodies to  
phospho-4EBP1 (Thr37/46), 4EBP1, phospho-p70S6K (Thr389), p70S6K 
(Cell Signaling, Inc., Beverly, MA, USA), p27, p21, or β-actin (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA). The membrane was then 
washed once for 15 min and twice for 5 min in 1 × PBS with 0.1% Tween-20. 
Next, the membrane was incubated in buffer A containing a 1:1000 dilution of 
horseradish peroxidase-linked goat anti-mouse IgG (Amersham Life Science, 
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Inc.). The washes were repeated, and the membrane was developed with 
chemiluminescent agent (ECL; Amersham Life Science, Inc.). The band 
densities were measured using TINA image software (Raytest, Straubenhardt, 
Germany). 
 
9. Immunohistochemistry 
Slices of kidney for Immunohistochemical staining were fixed in 10% 
neutral buffered formalin, processed in the standard manner, and 4 μm 
sections of paraffin embedded tissues were utilized. Slides were 
deparaffinized, hydrated in ethyl alcohol, and washed in tap water. Antigen 
retrieval was carried out in 10 mM sodium citrate buffer for 20 min using a 
Black and Decker vegetable steamer. For TCTP staining, the primary 
monoclonal anti-TCTP antibody (MBL International, Inc.) was diluted in 
1:200 with 2% casein in BSA and was applied for overnight incubation at 
room temperature. After washing, a secondary goat anti-mouse IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) was added for 20 
min, and the slides were then washed and incubated with a tertiary rabbit-
PAP complex for 20 min. DAB was added for 2 min and the slides were 
counterstained with hematolxylin. A semi-quantitative score for measuring 
the intensity of TCTP staining within glomeruli was determined by 
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examining thirty glomeruli in each section and by digital image analysis 
(MetaMorph version 4.6r5, Universal Imaging Corp., Downingtown, PA, 
USA) as previously described30. Briefly, the degree of staining was semi-
quantitated on a scale of 0~4+ and a staining score was obtained by 
multiplying the intensity of staining by the percentage of glomeruli staining 
for that intensity; these numbers were then added for each experimental 
animal to give the staining score. 
∑ (intensity of staining) × (% of glomeruli with that intensity) = staining 
score 
 
10. Immunofluorescence 
Slices of kidney for immunofluorescence staining were snap-frozen in 
optimal cutting temperature (OCT) solution and 4 μm sections of tissues were 
utilized. Slides were fixed in acetone for 10 min at 4°C, air dried for 10 min at 
room temperature, and blocked with 10% donkey serum for 20 min at room 
temperature. For TCTP staining, the monoclonal antibody to TCTP (MBL 
International, Inc.) was diluted in 1:200 with antibody diluent (DAKO, 
Glostrup, Denmark) and was applied for 3 hr at room temperature. After 
washing, Cy3 (red)-conjugated anti-mouse IgG antibody (Research 
Diagnostics, Inc., Flanders, NJ, USA) was added for 60 min. For 
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synaptopodin double staining, a 1:200 dilution of polyclonal anti-
synaptopodin antibody (Santa Cruz Biotechnology, Inc.) was applied, 
followed by Cy2 (green)-conjugated anti-goat IgG antibody. A semi-
quantitative score for measuring intensity of TCTP was determined as 
aforementioned. 
 
11. Assessment of hypertrophy 
Hypertrophy of cultured podocytes was assessed by measurement of 
cellular protein/cell counts and by flow cytometry. After seeding podocytes on 
100 mm dishes and serum restriction for 24 hr, medium was changed as above, 
and after 48 hr the cells were harvested with 0.05% trypsin and 0.25 mM/l 
ethylenediaminetetraacetic acid (EDTA), pelleted at 1,500 g for 5 min, and 
resuspended in PBS. Aliquots of podocytes were used for cell counts using a 
hemocytometer, and remaining cells were lysed in 0.5 M NaOH and total 
protein content was measured by using a modified Lowry method. To 
determine the cell size directly, cells were harvested by trypsinization after 48 
hr of treatment as above, fixed with 75% methanol, washed, and incubated 
with 100 μg/ml RNase and 10 μg/ml propidium iodide in PBS for 1 hr at 
37°C. Samples were analyzed by forward light scattering on a FACScan flow 
cytometer (BD Biosciences). Data were computer analyzed with Cell Quest 
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Pro software (BD Biosciences). 
Glomerular hypertrophy was determined by measuring glomerular volume 
(VG) as previously described31,32. Briefly, the surface areas of 20 glomeruli cut 
at the vascular pole on periodic acid-Schiff-stained tissue sections were traced 
along the outline of the capillary loops using a computer-assisted color image 
analyzer Image-Pro Ver. 2.0 (Media Cybernetics, Silver Spring, MD, USA). 
VG was calculated using the equation: VG=β/k × (Area)3/2, where β=1.38 is the 
shape coefficient for spheres, and k=1.1 is the size distribution coefficient. 
 
12. Statistical analysis 
All values are expressed as the mean ± standard error of the mean (SEM). 
Statistical analysis was performed using the statistical package SPSS for 
Windows Ver. 11.0 (SPSS, Inc., Chicago, IL, USA). Results were analyzed 
using the Kruskal-Wallis nonparametric test for multiple comparisons. 
Significant differences by the Kruskal-Wallis test were confirmed by the 
Mann-Whitney U test. P values less than 0.05 were considered to be 
statistically significant. 
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III. RESULTS 
 
1. Cultured podocytes studies 
 
A. Efficacy of TCTP knockdown by shRNA expressing lentivirus 
To test the silencing efficiency of shRNA, COS7 cells (American Type 
Culture Collection, Manassas, VA, USA) were cultured until reaching a 
confluency of 70% and co-transfected with pEGFP-C1-TCTP (4 μg) and 
pCMV-U6-TCTP shRNA-1, -2, -3, or -scrambled (4 μg) using Lipofectamine 
2000 (Invitrogen) as instructed by the manufacturer. Two days after co-
transfection, cells were examined microscopically for EGFP expression 
(Olympus IX51, Olympus, Japan). The knockdown efficacy of TCTP protein 
by shRNA was further confirmed by Western blot analysis. As seen in Figure 
1A, there was a significant reduction of green fluorescent signals in cells 
transfected with vectors containing pCMV-U6-TCTP shRNA-1 and -3 
compared to the scrambled vector. Western blot analysis further confirmed 
that TCTP-EGFP fusion protein levels were significantly decreased in COS7 
cells transfected with these vectors (Fig 1B). After then, cultured podocytes 
were incubated with lentiviruses produced with these expression cassettes for 
7 days. Lentivirus expressing TCTP shRNA-1 (LV-shTCTP1) inhibited the 
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protein expression of TCTP more efficiently compared to lentivirus 
expressing TCTP shRNA-3 (LV-shTCTP3) (Fig. 1C). Based on these results, 
all subsequent in vitro and in vivo experiments were performed with lentivirus 
expressing TCTP shRNA-1 (LV-shTCTP1). 
(A) 
 
 
 
 
 
(B)                          (C) 
 
 
 
 
Figure 1. Efficiency of RNA interference for TCTP. (A) Fluorescent 
microscopic findings of COS7 cells 2 days after co-transfection with pEGFP-
C1-TCTP and pCMV-U6-TCTP shRNA-1, -2, -3, or -scrambled. There was a 
significant reduction of green fluorescent signals in cells transfected with 
vectors containing pCMV-U6-TCTP shRNA-1 and -3 compared to the 
scrambled vector. (B) A representative Western blot of TCTP with COS7 cells 
co-transfected with pEGFP-C1-TCTP and pCMV-U6-TCTP shRNA-1, -2, -3, 
or -scrambled (representative of five blots). TCTP-EGFP fusion protein levels 
were significantly decreased in COS7 cells transfected with vectors 
containing pCMV-U6-TCTP shRNA-1 and -3 compared to the scrambled 
vector. (C) A representative Western blot of TCTP with podocytes incubated 
with lentiviruses expressing TCTP shRNA-1 (LV-shTCTP1) and shRNA-3 
(LV-shTCTP3) (representative of five blots). LV-shTCTP1 inhibited the 
protein expression of TCTP more efficiently compared to LV-shTCTP3. 
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B. TCTP mRNA and protein expression in cultured podocytes 
TCTP mRNA expression assessed by real-time PCR was significantly 
increased in HG- and ANG II-stimulated podocytes. Compared to NG cells, 
there were 1.5- and 1.8-folds increases in the ratio of TCTP mRNA/18s rRNA 
in cultured podocytes exposed to HG and ANG II, respectively (p<0.05) (Fig. 
2A). TCTP protein expression, assessed by Western blot, showed a similar 
pattern to its mRNA expression. HG and ANG II significantly increased TCTP 
protein expression in cultured podocytes and L-158,809 significantly 
abrogated HG-induced TCTP protein expression (Fig. 2B). On the other hand, 
mannitol had no effect on TCTP mRNA and protein expression (data not 
shown). 
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Figure 2. TCTP mRNA and protein expression in cultured podocytes. (A) The 
ratios of TCTP mRNA/18s rRNA were significantly increased in cultured 
podocytes exposed to HG and ANG II by 1.5- and 1.8-folds compared to NG 
cells. (B) A representative Western blot of TCTP protein in cultured podocytes 
exposed to NG, HG, HG+L-158,809 (ARB), and NG+ANG II (representative 
of four blots). HG and ANG II significantly increased TCTP protein 
expression in cultured podocytes and L-158,809 significantly abrogated HG-
induced TCTP protein expression. *; p<0.05 vs. NG group, #; p<0.05 vs. HG 
group. 
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C. Effect of TCTP inhibition on HG-induced 4EBP1 and p70S6K 
activation 
HG significantly increased phospho-4EBP1 and phospho-p70S6K protein 
expression in cultured podocytes (p<0.01), and these increases in 4EBP1 and 
p70S6K activation were significantly ameliorated by LV-shTCTP1 by 54.8% 
(p<0.05) and 79.0% (p<0.01), respectively. In contrast, there were no 
differences in 4EBP1 and p70S6K protein expression among the groups. On 
the other hand, LV-shTCTPscrambled had no effect on the expression of 
TCTP, phospho-4EBP1, 4EBP1, phospho-p70S6K, and p70S6K protein 
expression in cultured podocytes (Fig. 3). 
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Figure 3. . A representative Western blot of TCTP, phospho-4EBP1, 4EBP1, 
phospho-p70S6K, and p70S6K in cultured podocytes (representative of four 
blots). phospho-4EBP1 and phospho-p70S6K protein expression were 
significantly increased in HG-stimulated podocytes, and these increases in 
4EBP1 and p70S6K activation were significantly ameliorated by LV-
shTCTP1. In contrast, there were no differences in 4EBP1 and p70S6K 
protein expression among the groups. On the other hand, LV-
shTCTPscrambled had no effect on the expression of TCTP, phospho-4EBP1, 
4EBP1, phospho-p70S6K, and p70S6K protein expression in cultured 
podocytes. *; p<0.01 vs. NG with LV-shTCTPscrambled group, #; p<0.05 vs. 
HG with LV-shTCTPscrambled group, †; p<0.01 vs. HG with LV-
shTCTPscrambled group. 
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D. Effect of TCTP inhibition on HG-induced p27 and p21 protein 
expression 
The protein expression of p27 was significantly increased by 1.8-fold in 
HG-stimulated podocytes transfected with LV-shTCTPscrambled compared to 
corresponding NG cells (p<0.05), and this increase in p27 protein expression 
in cultured podocytes exposed to HG was significantly attenuated by LV-
shTCTP1 by 66.7% (p<0.05). The protein expression of p21 showed a similar 
pattern to p27 protein expression, but did not reach statistical significance (Fig. 
4). 
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Figure 4. A representative Western blot of TCTP, p27, and p21 in cultured 
podocytes transfected with LV-shTCTPscrambled and LV-shTCTP1. 
(representative of four blots). The protein expression of p27 was significantly 
increased by 1.8-fold in HG-stimulated podocytes transfected with LV-
shTCTPscrambled compared to corresponding NG cells, and this increase in 
p27 protein expression in cultured podocytes exposed to HG was significantly 
attenuated by LV-shTCTP1 by 66.7%. The protein expression of p21 showed 
a similar pattern to p27 protein expression, but did not reach statistical 
significance. *; p<0.05 vs. NG with LV-shTCTPscrambled group, #; p<0.05 vs. 
HG with LV-shTCTPscrambled group. 
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E. Effect of TCTP on podocyte hypertrophy 
Cellular protein content was significantly higher in HG-stimulated 
podocytes transfected with LV-shTCTPscrambled compared to corresponding 
NG cell with no significant change in cell numbers, suggesting cellular 
hypertrophy. A 1.7-fold increase in the ratio of protein/cell numbers was 
observed in podocytes exposed to HG with LV-shTCTPscrambled transfection, 
and the increment in the ratio of protein/cell numbers by HG was significantly 
inhibited by LV-shTCTP1 by 75.0% (p<0.05) (Fig. 5A). In contrast, LV-
shTCTPscrambled had no effect on the ratio of protein/cell numbers in 
cultured podocytes exposed to NG. 
Cellular hypertrophy was also confirmed by FACScan flow cytometer (Fig. 
5B). The relative cell size, determined by mean forward light scattering, was 
25% larger in HG-stimulated podocytes transfected with LV-
shTCTPscrambled compared to corresponding NG cells, and LV-shTCTP1 
significantly abrogated the increase in cell size of HG podocytes by 85% 
(p<0.05). 
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Figure 5. Assessments of podocyte hypertrophy. (A) Protein/cell numbers of 
podocytes. A 1.7-fold increase in the ratio of protein/cell numbers was 
observed in podocytes exposed to HG with LV-shTCTPscrambled transfection, 
and the increment in the ratio of protein/cell numbers by HG was significantly 
inhibited by LV-shTCTP1. In contrast, LV-shTCTPscrambled had no effect on 
the ratio of protein/cell numbers in cultured podocytes exposed to NG. *; 
p<0.05 vs. NG and NG with LV-shTCTPscrambled groups, #; p<0.05 vs. HG 
with LV-shTCTPscrambled group. (B) A representative FACScan of 
podocytes exposed to NG+LV-shTCTPscrambled, HG+LV-shTCTPscrambled, 
and HG+LV-shTCTP1. The relative cell size, determined by mean forward 
light scattering, was 25% larger in HG-stimulated podocytes transfected with 
LV-shTCTPscrambled compared to corresponding NG cells, and LV-shTCTP1 
significantly abrogated the increase in cell size of HG podocytes by 85.0%. 
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2. Animal studies 
 
A. Animal data 
All animals gained weight over the 6-week experimental period, but 
weight gain was highest in C mice (p<0.01). The ratio of kidney weight to 
body weight in DM mice (1.63±0.04%) was significantly higher than those 
in C (1.13±0.03%) (p<0.01) and in DM+LV-shTCTP1 mice (1.27±0.04%) 
(p<0.05). The mean blood glucose levels of C, C+LV-shTCTP1, DM, and 
DM+LV-shTCTP1 mice were 123.2±6.3 mg/dl, 121.1±6.8 mg/dl, 
462.7±41.5 mg/dl, and 475.1±36.2 mg/dl, respectively (p<0.01). Compared 
to the C group (4.07±0.96 μg/day), 24-hr urinary albumin excretion was 
significantly higher in DM mice (14.25±3.19 μg/day) (p<0.01), and LV-
shTCTP1 treatment partly reversed the increase in albuminuria in DM mice 
(8.16±1.80 μg/day) (p<0.05). The serum levels of BUN and creatinine were 
comparable among the four groups. 
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B. Glomerular TCTP protein expression 
Glomerular TCTP protein expression assessed by Western blot was 
significantly higher in DM compared to C mice (p<0.005), and LV-shTCTP1 
treatment significantly ameliorated the increase in TCTP protein expression in 
diabetic glomeruli (p<0.01). Densitometric quantitation revealed 7.8-fold 
increase in TCTP protein expression in DM versus C mice, and LV-shTCTP1 
treatment blocked the increase by 53.8% (Fig. 6). 
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Figure 6. A representative Western blot of TCTP in C, C+LV-shTCTP1, DM, 
and DM+LV-shTCTP1 glomeruli (representative of four blots). Glomerular 
TCTP protein expression was significantly higher in DM compared to C mice, 
and LV-shTCTP1 treatment significantly ameliorated the increase in TCTP 
protein expression in diabetic glomeruli. Densitometric quantitation revealed 
7.8-fold increase in TCTP protein expression in DM versus C mice, and LV-
shTCTP1 treatment blocked the increase by 53.8%. *; p<0.005 vs. C and 
C+LV-shTCTP1 groups, #; p<0.01 vs. DM group. 
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C. Immunohistochemical staining for glomerular TCTP  
Immunohistochemical staining for glomerular TCTP confirmed the 
Western blot findings. The staining for TCTP within glomeruli was 
significantly stronger in DM compared to C mice, and LV-shTCTP1 treatment 
significantly attenuated the increase in TCTP protein expression in DM 
glomeruli (p<0.05). The mean semi-quantitative staining scores for 
glomerular TCTP were significantly higher in DM (32.1±5.6) compared to C 
(10.0±2.4) and DM+LV-shTCTP1 mice (16.6±3.4) (p<0.05) (Fig. 7). 
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Figure 7. Immunohistochemical staining for TCTP in C, C+LV-shTCTP1, 
DM, and DM+LV-shTCTP1 mice. Glomerular TCTP staining was 
significantly stronger in DM compared to C mice, and LV-shTCTP1 treatment 
significantly attenuated the increase in TCTP protein expression in DM 
glomeruli. IHC score for TCTP within the glomeruli was significantly higher 
in DM mice compared to C mice, and LV-shTCTP1 treatment significantly 
inhibited this increase in DM mice. *; p<0.05 vs. Other groups. 
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D. Localization of TCTP protein expression 
Double immunofluorescence staining for TCTP and synaptopodin revealed 
that podocytes were the main cells responsible for the increase in TCTP 
protein under diabetic conditions (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8. Double immunofluorescence staining for TCTP (red) and 
synaptopodin (green) in C and DM mice. Compared to C, 
immunofluorescence staining for TCTP was increased in DM glomeruli, and 
double immunofluorescence staining revealed that the increase in TCTP 
protein expression was mainly attributed to its increase in podocytes (× 400). 
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E. Effect of TCTP inhibition on 4EBP1 and p70S6K activation 
Figure 9 shows a representative Western blot of equal amounts of protein 
from the lysates of sieved C, C+LV-shTCTP1, DM, and DM+LV-shTCTP1 
glomeruli at 6-week after streptozotocin injection. Phospho-4EBP1 and 
phospho-p70S6K protein expression were significantly increased in DM 
glomeruli (p<0.01), and the administration of LV-shTCTP1 significantly 
abrogated these increases in 4EBP1 and p70S6K activation in DM glomeruli 
by 45.8% and 43.1%, respectively (p<0.05). In contrast, there were no 
differences in 4EBP1 and p70S6K protein expression among the four groups 
(Fig. 9). 
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Figure 9. A representative Western blot of glomerular phospho-4EBP1, 
4EBP1, phospho-p70S6K, and p70S6K in C, C+LV-shTCTP1, DM, and 
DM+LV-shTCTP1 mice (representative of four blots). Phospho-4EBP1 and 
phospho-p70S6K protein expression were significantly increased in DM 
glomeruli, and the administration of LV-shTCTP1 significantly abrogated 
these increases in 4EBP1 and p70S6K activation in DM glomeruli by 45.8% 
and 43.1% respectively. In contrast, there were no differences in 4EBP1 and 
p70S6K protein expression among the four groups. *; p<0.01 vs. C and 
C+LV-shTCTP1 groups, #; p<0.05 vs. DM group. 
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F. Effect of TCTP inhibition on glomerular p27 and p21 protein 
expression 
Glomerular p27 and p21 protein expression assessed by Western blot were 
significantly higher in DM compared to C mice, and the administration of LV-
shTCTP1 significantly ameliorated these increases in p27 and p21 protein 
expression. Densitometric quantitation revealed 4.3- and 2.3-folds increases in 
glomerular p27 and p21 protein expression in DM versus C mice, and LV-
shTCTP1 treatment blocked these increases by 41.9% and 38.1%, respectively 
(p<0.05). 
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Figure 10. A representative Western blot of glomerular p27 and p21 in C, 
C+LV-shTCTP1, DM, and DM+LV-shTCTP1 mice (representative of four 
blots). Glomerular p27 and p21 protein expression were significantly higher 
in DM compared to C mice, and the administration of LV-shTCTP1 
significantly ameliorated these increases in p27 and p21 protein expression. 
Densitometric quantitation revealed 4.3- and 2.3-folds increases in glomerular 
p27 and p21 protein expression in DM versus C mice, and LV-shTCTP1 
treatment blocked these increases by 41.9% and 38.1%, respectively. *; 
p<0.05 vs. Other groups. 
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G. Effect of TCTP inhibition on glomerular hypertrophy 
The mean glomerular volume in DM (1.94±0.11 × 105 μm3) was 31.1% 
larger than in C mice (1.34±0.13 × 105 μm3) at 6-week after DM induction, 
and LV-shTCTP1 administration significantly attenuated glomerular 
hypertrophy in DM mice (1.65±0.16 × 105 μm3) (p<0.05). 
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IV. DISCUSSION 
 
Previous studies have demonstrated TCTP plays an important role in 
cellular or organ hypertrophy22,33,34, but its functional significance in podocyte 
hypertrophy under diabetic conditions has never been explored. This study 
demonstrates for the first time that TCTP expression is increased in high 
glucose-stimulated podocytes and in experimental diabetic glomeruli. In 
addition, the results of the present study showing that inhibition of TCTP 
abrogates podocyte and glomerular hypertrophy via inhibiting 
phosphorylation of 4EBP1 and p70S6K, two important mTOR target 
molecules35, and CKIs expression suggest that TCTP is involved in the 
process of podocyte hypertrophy in diabetic nephropathy. 
Even though TCTP was originally identified as a growth-related protein in 
a mouse ascitic tumor and in mouse erythroleukemia36,37, it was demonstrated 
as a protein triggering histamine in basophils and has been called ‘IgE-
dependent histamine release factor’18. However, accumulating evidences have 
shown that TCTP is widely expressed in various organisms and that its 
sequence is highly conserved among species, suggesting that TCTP may play 
a role in many essential cellular functions38,39. TCTP is known to be regulated 
at both the transcriptional and translational levels in response to a wide range 
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of extracellular stimuli and cellular conditions19,38,40. Growth signals, 
numerous cytokines, and various stress conditions including oxidative stress, 
heat shock, and endoplasmic reticulum stress have been found to induce 
TCTP expression41-46. In addition, the levels of TCTP expression are reported 
to be high in actively proliferating cells such as malignant cells, and to be 
reduced when tumor cells undergo reversion47. In this study, TCTP mRNA 
and protein expression are increased in podocytes exposed to high glucose 
medium and in diabetic glomeruli. Moreover, TCTP expression in cultured 
podocytes is also increased by ANG II, an important mediator in the 
pathogenesis of diabetic nephropathy through inducing extracellular matrix 
synthesis, oxidative stress, and hypertrophy in glomerular cells, and high 
glucose-induced TCTP expression is ameliorated by ARB treatment. Since 
local renin-angiotensin system is known to be activated within podocytes 
under diabetic conditions48, I surmise that numerous cytokines, oxidative 
stress, and increased ANG II production under diabetic conditions may 
contribute to the increase in TCTP expression in podocytes though mitotically 
inactive. 
Besides its original histamine releasing function, TCTP has been 
implicated in various intracellular functions. TCTP was reported to have 
properties of a tubulin-binding protein that was associated with microtubules 
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during G1, S, G2 and early M phase of the cell cycle, bound to the mitotic 
spindle at metaphase, and was detached from the spindle during metaphase-
anaphase transition49. In addition, overexpression of TCTP resulted in cell 
growth retardation and increased cell size and in alterations of cell 
morphology49. Based on the fact that TCTP was directly phosphorylated in 
mitosis in vivo and by the mitotic kinase Plk in vitro and that overexpression 
of a Plk phosphorylation site-deficient mutant of TCTP disrupted the 
completion of mitosis, TCTP was also considered a key mitotic target of Plk 
for regulating anaphase progression50. In a recent study, checkpoint protein 
with FHA and RING finger domain (Chfr), which plays an important function 
in cell cycle progression, was demonstrated to interact and colocalize with 
TCTP to the mitotic spindle51. Moreover, Hsu et al22 revealed that reducing 
TCTP levels by RNA interference results in decreases in cell size, cell number, 
and organ size, suggesting that TCTP was essential for growth and 
proliferation in Drosophila. Taken together, TCTP is believed to be important 
for cell growth and division. Since diabetic nephropathy is characterized by 
renal hypertrophy, there is a possibility that TCTP may play role in the 
pathogenesis of glomerular and tubular hypertrophy in diabetic nephropathy. 
Up to date, however, the impact of TCTP on glomerular cells hypertrophy 
under diabetic conditions has never been explored. The present study shows 
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for the first time that TCTP expression is increased in podocytes under 
diabetic conditions and inhibition of TCTP by shRNA attenuates glomerular 
hypertrophy in experimental diabetic mice and cellular hypertrophy in high 
glucose-stimulated podocytes, suggesting that TCTP is involved in the 
hypertrophic process in podocytes under diabetic conditions. 
Recent studies have proven that TCTP interacts with Rheb, a small 
GTPase, which is a critical regulator of mTOR52-54. Rheb binds to FK506 
binding protein 38 (FKBP38), an endogenous inhibitor of mTOR, in a GTP-
dependent manner and as a result, prevents the interaction of FKBP38 with 
mTOR and leads to an activation of mTOR52. In addition, TCTP 
overexpression induces activation of PI3 kinase, which can in turn activate 
mTOR23. mTOR is a serine/threonine protein kinase and exists in two distinct 
multiprotein complex, mTORC1 and mTORC255. mTORC1 is rapamycin-
sensitive and is consist of mTOR, raptor, and mLST8, and regulates 
transcription, ribosome protein synthesis, and mRNA translation through 
phosphorylation of its major substrates, 4EBP1 and p70S6K56. In terms of the 
functional role of mTOR in diabetic nephropathy, recent several investigations 
have revealed that mTOR is involved in the pathogenesis of glomerular and 
tubular hypertrophy. Renal hypertrophy with increased phosphorylation of 
4EBP1 and/or p70S6K in the kidneys was abrogated by rapamycin, a specific 
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and potent inhibitor of mTOR, in animal model of type I and type II 
diabetes14-17,57. In addition, p70S6K knockout ameliorated renal hypertrophy 
in diabetic mice58, while overexpression of a constitutive active form of 
p70S6K resulted in increased cell size of cultured mouse proximal tubule 
cells59. These findings suggest that activation of mTOR signaling pathway 
causes renal hypertrophy under diabetic conditions by stimulating the 
initiation and elongation phase of mRNA translation through phosphorylation 
of p70S6K and 4EBP1. In agreement with the results of previous studies, I 
notice that phosphorylation of 4EBP1 and p70S6K are significantly increased 
in high glucose stimulated podocytes and in diabetic glomeruli, and TCTP 
inhibition ameliorates podocyte and glomerular hypertrophy as well as 
phosphorylation of these mTOR target molecules, suggesting that increased 
TCTP expression may contribute to podocyte hypertrophy under diabetic 
conditions by regulating the mRNA translation pathways. 
Cell-cycle entry and progression through the cell cycle depend on the 
expression and activation of CDKs and their regulatory subunits, cyclins, and 
the kinase activity of cyclin/CDK complexes is negatively regulated by 
CKIs60. In cultured rat mesangial cells, high glucose, in the absence of other 
exogenous growth factors, was found to induce p27Kip1 protein expression61. 
This high glucose-stimulated expression of p27Kip1 involved the activation of 
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protein kinase C and depended partly on the induction of transforming growth 
factor-β61. In addition, p27Kip1 antisense oligonucleotides treatment prevented 
glucose-induced mesangial cell hypertrophy, and resulted in a proliferative 
phenotype61. Glomerular p27Kip1 protein expression was increased in diabetic 
db/db mice, a model of type 2 diabetes, and in murine streptozotocin type I 
diabetes62. p21Cip1 protein was also enhanced in 3- and 9-day streptozotocin-
induced diabetic glomeruli assessed by immunohistochemical staining63. In 
contrast to mesangial cells, mature podocytes do not actively synthesize DNA 
nor proliferate under normal conditions due to high levels of CKIs 
expression64. Under diabetic conditions, however, podocytes also undergo 
hypertrophic processes like mesangial cells, resulting in increased cell size5,7. 
Petermann et al7 demonstrated that mechanical stretch, an in vitro condition of 
increased intraglomerular capillary pressure, reduced cell cycle progression 
and induced hypertrophy in cultured podocytes. Another previous study by Xu 
et al5 showed that high glucose per se also induced podocyte hypertrophy, 
which was associated with increased p27Kip1 expression. Taken together, CKIs 
is confirmed to play an important role in hypertrophy of glomerular cells 
under diabetic conditions. 
Recently, several studies have suggested that an interaction between PI3 
kinase/Akt/mTOR pathway and cyclin/CDKs/CKIs expression. High glucose 
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induced PI3 kinase/Akt activation, p21Cip1 mRNA and protein expression, and 
cellular hypertrophy in LLC-PK1 cells, and these changes were abrogated by 
LY294002, a PI3 kinase inhibitor, indicating that PI3 kinase/Akt pathway 
were involved in p21Cip1 expression65. In addition, renal expression of p21Cip1 
and p27Kip1 in streptozotocin-induced diabetic mice were ameliorated by 
rapamycin59. Similarly, in this study, I found that the increases in p21Cip1 and 
p27Kip1 expression in high glucose-stimulated podocytes and in experimental 
diabetic glomeruli were attenuated by TCTP inhibition along with reduced 
phosphorylation of mTOR target molecules. These findings suggest that 
mTOR pathway and its possible upstream activator TCTP may provoke 
cellular hypertrophy via inducing CKIs expression under diabetic conditions. 
In contrast, Hong et al66 have shown that activation of serum- and 
glucocorticoid-inducible kinase 1 (SGK1) by mTOR may promote G1 
progression through phosphorylation and cytoplasmic mislocalization of 
p27Kip1. Moreover, several investigators have reported that mTOR inhibitor 
blocks cell cycle progression and cell proliferation through disrupting cyclin 
D1-CDK4 complexes, and upregulates p27Kip1 at both mRNA and protein 
levels and prolongs its half-life and facilitates the formation of complexes 
between p27Kip1 and CDK/cyclins67,68. PI3 kinase inhibitor was also shown to 
increase p21Cip1 expression in phorbol 12-myristate 13-acetate-induced human 
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leukemia cells69. I assume that these absolutely opposite effects of PI3 
kinase/Akt/mTOR on cell cycle progression may be largely due to the 
differences in cells used for experiments (normal cells versus malignant cells) 
and diverse experiment conditions. 
Transfection using lentivirus is an exciting gene delivery tool because of 
its ability to efficiently transduce both dividing and non-dividing target cell 
populations25. In addition, the transfection efficiencies of synthetic siRNA 
oligonucleotide and plasmid-based delivery system have been known to be 
very low in mature podocytes. Moreover, TCTP has a relatively long half-
life70, and to some extent, its expression is controlled at the level of translation 
from the pre-existing mRNA19,38. Based on these findings, I considered 
transfection with lentivirus containing TCTP shRNA as an optimal method to 
establish long-lasting knockdown of TCTP gene and used this technique in 
this study. Even though the introduction of lentivirus containing TCTP shRNA 
in the present in vivo study does not inhibit TCTP specifically in podocytes, I 
presume that the abrogation of glomerular hypertrophy in diabetic mice by 
TCTP shRNA may be partially attributed to reduced podocyte hypertrophy. 
In conclusion, I demonstrate that TCTP expression is increased in 
podocytes under diabetic conditions. In addition, inhibition of TCTP 
ameliorates the activation of mTOR target molecules, 4EBP1 and p70S6K, 
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and CKIs expression along with reduced podocytes hypertrophy. These 
findings suggest that TCTP may play an important role in the process of 
podocyte hypertrophy under diabetic conditions via stimulating mRNA 
translation and inducing cell cycle arrest at the G1/S interphase. 
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V. CONCLUSION 
 
In this study, I investigated whether TCTP expression was increased in 
high glucose-stimulated podocytes and in experimental diabetic glomeruli. In 
addition, to elucidate the functional role of TCTP in podocyte hypertrophy, I 
examined the changes in the expression of effectors of mRNA translation, 
CKIs, and podocyte hypertrophy under diabetic condition after TCTP 
inhibition. 
 
1. Compared to NG cells, TCTP mRNA and protein expression were 
significantly increased in podocytes exposed to HG, and this increase in 
TCTP expression was abrogated by ARB treatment. 
2. ANG II induced TCTP mRNA and protein expression in cultured podocytes. 
3. The protein expression of phospho-4EBP1, phospho-p70S6K, and p27 were 
significantly increased in HG-stimulated podocytes compared to NG cells, 
and these increases were significantly ameliorated by LV-shTCTP. 
4. TCTP inhibition significantly attenuated cell size in cultured podocytes 
cultured under HG medium. 
5. Glomerular TCTP expression was significantly higher in DM compared 
with C mice. 
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6. Double immunofluorescence staining for TCTP and synaptopodin revealed 
that podocytes were the main cells responsible for the increase in TCTP 
protein expression in diabetic glomeruli. 
7. Administration of LV-shTCTP significantly abrogated the increase in 
phospho-4EBP1, phospho-p70S6K, p27, and p21 protein expression in 
diabetic glomeruli along with reduced glomerular size. 
 
In conclusion, TCTP expression is increased in podocytes under diabetic 
conditions and inhibition of TCTP ameliorates the activation of mTOR target 
molecules, 4EBP1 and p70S6K, and CKIs expression, along with reduced 
podocyte and glomerular size. These findings suggest that TCTP may play an 
important role in the process of podocyte hypertrophy under diabetic 
conditions via regulating mRNA translation and inducing cell cycle arrest at 
the G1/S interphase. 
 
REFERENCES 
 
1. Baumgartl HJ, Sigl G, Banholzer P, Haslbeck M, Standl E. On the 
prognosis of IDDM patients with large kidneys. Nephrol Dial Transplant. 
1998;13:630-4. 
2. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal 
hypertrophy. Kidney Int. 1999;56:393-405. 
3. Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K. p27(Kip1) 
Knockout mice are protected from diabetic nephropathy: evidence for 
p27(Kip1) haplotype insufficiency. Kidney Int. 2005;68:1583-9. 
4. Menini S, Iacobini C, Oddi G, Ricci C, Simonelli P, Fallucca S, et al. 
Increased glomerular cell (podocyte) apoptosis in rats with 
streptozotocin-induced diabetes mellitus: role in the development of 
diabetic glomerular disease. Diabetologia. 2007;50:2591-9. 
5. Xu ZG, Yoo TH, Ryu DR, Cheon Park H, Ha SK, Han DS, et al. 
Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-
stimulated podocytes and in diabetic glomeruli. Kidney Int. 2005;67:944-
52. 
6. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, et al. 
Podocyte injury promotes progressive nephropathy in zucker diabetic 
fatty rats. Lab Invest. 2002;82:25-35. 
7. Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa 
T, et al. Mechanical stretch induces podocyte hypertrophy in vitro. 
Kidney Int. 2005;67:157-66. 
8. Ruster C, Bondeva T, Franke S, Forster M, Wolf G. Advanced glycation 
end-products induce cell cycle arrest and hypertrophy in podocytes. 
Nephrol Dial Transplant. 2008;23:2179-91. 
9. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-
interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent 
kinases. Cell. 1993;75:805-16. 
10. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et 
al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-
beta and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22. 
11. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D. 
mRNA translation: unexplored territory in renal science. J Am Soc 
56 
 
Nephrol. 2006;17:3281-92. 
12. Kasinath BS, Feliers D, Sataranatarajan K, Choudhury GG, Lee MJ, 
Mariappan MM. Regulation of mRNA translation in renal physiology 
and disease. Am J Physiol Renal Physiol. 2009;297:F1153-65. 
13. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Ghosh 
Choudhury G, Feliers D. Novel mechanisms of protein synthesis in 
diabetic nephropathy--role of mRNA translation. Rev Endocr Metab 
Disord. 2008;9:255-66. 
14. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, 
Barnes JL, et al. Regulation of elongation phase of mRNA translation in 
diabetic nephropathy: amelioration by rapamycin. Am J Pathol. 
2007;171:1733-42. 
15. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, 
Musi N, et al. A role for AMP-activated protein kinase in diabetes-
induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292:F617-
27. 
16. Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, et al. 
Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic 
nephropathy. Kidney Int. 2005;68:552-61. 
17. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, et 
al. The mTOR pathway is highly activated in diabetic nephropathy and 
rapamycin has a strong therapeutic potential. Biochem Biophys Res 
Commun. 2009;384:471-5. 
18. MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM. Molecular 
identification of an IgE-dependent histamine-releasing factor. Science. 
1995;269:688-90. 
19. Bommer UA, Borovjagin AV, Greagg MA, Jeffrey IW, Russell P, Laing 
KG, et al. The mRNA of the translationally controlled tumor protein 
P23/TCTP is a highly structured RNA, which activates the dsRNA-
dependent protein kinase PKR. RNA. 2002;8:478-96. 
20. Cans C, Passer BJ, Shalak V, Nancy-Portebois V, Crible V, Amzallag N, 
et al. Translationally controlled tumor protein acts as a guanine 
nucleotide dissociation inhibitor on the translation elongation factor 
eEF1A. Proc Natl Acad Sci U S A. 2003;100:13892-7. 
21. Dong X, Yang B, Li Y, Zhong C, Ding J. Molecular basis of the 
57 
 
acceleration of the GDP-GTP exchange of human Rheb by human TCTP. 
J Biol Chem. 2009;284:23754-64. 
22. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW. Drosophila TCTP is essential 
for growth and proliferation through regulation of dRheb GTPase. Nature. 
2007;445:785-8. 
23. Kim M, Jung J, Lee K. Roles of ERK, PI3 kinase, and PLC-c pathways 
induced by overexpression of translationally controlled tumor protein in 
HeLa cells. Arch Biochem Biophys. 2009;485:82-7. 
24. Dittgen T, Nimmerjahn A, Komai S, Licznerski P, Waters J, Margrie TW, 
et al. Lentivirus-based genetic manipulations of cortical neurons and their 
optical and electrophysiological monitoring in vivo. Proc Natl Acad Sci 
U S A. 2004;101:18206-11. 
25. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline 
transmission and tissue-specific expression of transgenes delivered by 
lentiviral vectors. Science. 2002;295:868-72. 
26. Lois C, Refaeli Y, Qin XF, Van Parijs L. Retroviruses as tools to study 
the immune system. Curr Opin Immunol. 2001;13:496-504. 
27. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, 
Kriz W, et al. Rearrangements of the cytoskeleton and cell contacts 
induce process formation during differentiation of conditionally 
immortalized mouse podocyte cell lines. Exp Cell Res. 1997;236:248-58. 
28. Kim JJ, Li JJ, Jung DS, Kwak SJ, Ryu DR, Yoo TH, et al. Differential 
expression of nephrin according to glomerular size in early diabetic 
kidney disease. J Am Soc Nephrol. 2007;18:2303-10. 
29. Kang SW, Adler SG, Lapage J, Natarajan R. p38 MAPK and MAPK 
kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. 
Kidney Int. 2001;60:543-52. 
30. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, 
et al. Nephrin redistribution on podocytes is a potential mechanism for 
proteinuria in patients with primary acquired nephrotic syndrome. Am J 
Pathol. 2001;158:1723-31. 
31. Weibel ER, Gomez DM. A principle for counting tissue structures on 
random sections. J Appl Physiol. 1962;17:343-8. 
32. El-Aouni C, Herbach N, Blattner SM, Henger A, Rastaldi MP, Jarad G, et 
al. Podocyte-specific deletion of integrin-linked kinase results in severe 
58 
 
glomerular basement membrane alterations and progressive 
glomerulosclerosis. J Am Soc Nephrol. 2006;17:1334-44. 
33. Thomas G. Translational control of mRNA expression during the early 
mitogenic response in Swiss mouse 3T3 cells: identification of specific 
proteins. J Cell Biol. 1986;103:2137-44. 
34. Bohm H, Benndorf R, Gaestel M, Gross B, Nurnberg P, Kraft R, et al. 
The growth-related protein P23 of the Ehrlich ascites tumor: translational 
control, cloning and primary structure. Biochem Int. 1989;19:277-86. 
35. Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin 
proteins in cell growth control. Microbiol Mol Biol Rev. 2005;69:79-100. 
36. Yenofsky R, Bergmann I, Brawerman G. Messenger RNA species 
partially in a repressed state in mouse sarcoma ascites cells. Proc Natl 
Acad Sci U S A. 1982;79:5876-80. 
37. Thomas G, Luther H. Transcriptional and translational control of 
cytoplasmic proteins after serum stimulation of quiescent Swiss 3T3 cells. 
Proc Natl Acad Sci U S A. 1981;78:5712-6. 
38. Bommer UA, Lazaris-Karatzas A, De Benedetti A, Nurnberg P, Benndorf 
R, Bielka H, et al. Translational regulation of the mammalian growth-
related protein P23: involvement of eIF-4E. Cell Mol Biol Res. 
1994;40:633-41. 
39. Chitpatima ST, Makrides S, Bandyopadhyay R, Brawerman G. 
Nucleotide sequence of a major messenger RNA for a 21 kilodalton 
polypeptide that is under translational control in mouse tumor cells. 
Nucleic Acids Res. 1988;16:2350. 
40. Bonnet C, Perret E, Dumont X, Picard A, Caput D, Lenaers G. 
Identification and transcription control of fission yeast genes repressed 
by an ammonium starvation growth arrest. Yeast. 2000;16:23-33. 
41. Gnanasekar M, Dakshinamoorthy G, Ramaswamy K. Translationally 
controlled tumor protein is a novel heat shock protein with chaperone-
like activity. Biochem Biophys Res Commun. 2009;386:333-7. 
42. Yan Y, Weaver VM, Blair IA. Analysis of protein expression during 
oxidative stress in breast epithelial cells using a stable isotope labeled 
proteome internal standard. J Proteome Res. 2005;4:2007-14. 
43. Oikawa K, Ohbayashi T, Mimura J, Fujii-Kuriyama Y, Teshima S, 
Rokutan K, et al. Dioxin stimulates synthesis and secretion of IgE-
59 
 
dependent histamine-releasing factor. Biochem Biophys Res Commun. 
2002;290:984-7. 
44. Teshima S, Rokutan K, Nikawa T, Kishi K. Macrophage colony-
stimulating factor stimulates synthesis and secretion of a mouse homolog 
of a human IgE-dependent histamine-releasing factor by macrophages in 
vitro and in vivo. J Immunol. 1998;161:6356-66. 
45. Nielsen HV, Johnsen AH, Sanchez JC, Hochstrasser DF, Schiotz PO. 
Identification of a basophil leukocyte interleukin-3-regulated protein that 
is identical to IgE-dependent histamine-releasing factor. Allergy. 
1998;53:642-52. 
46. Bommer UA, Thiele BJ. The translationally controlled tumour protein 
(TCTP). Int J Biochem Cell Biol. 2004;36:379-85. 
47. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Geant A, Beaucourt S, et al. 
Translationally controlled tumor protein is a target of tumor reversion. 
Proc Natl Acad Sci U S A. 2004;101:15364-9. 
48. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, et al. Activation of 
the renin-angiotensin system within podocytes in diabetes. Kidney Int. 
2007;71:1019-27. 
49. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer 
UA. The growth-related, translationally controlled protein P23 has 
properties of a tubulin binding protein and associates transiently with 
microtubules during the cell cycle. J Cell Sci. 1999;112 (Pt 8):1257-71. 
50. Yarm FR. Plk phosphorylation regulates the microtubule-stabilizing 
protein TCTP. Mol Cell Biol. 2002;22:6209-21. 
51. Burgess A, Labbe JC, Vigneron S, Bonneaud N, Strub JM, Van 
Dorsselaer A, et al. Chfr interacts and colocalizes with TCTP to the 
mitotic spindle. Oncogene. 2008. 
52. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and 
regulates the mTOR kinase. Curr Biol. 2005;15:702-13. 
53. Dunlop EA, Dodd KM, Seymour LA, Tee AR. Mammalian target of 
rapamycin complex 1-mediated phosphorylation of eukaryotic initiation 
factor 4E-binding protein 1 requires multiple protein-protein interactions 
for substrate recognition. Cell Signal. 2009;21:1073-84. 
54. Ma D, Bai X, Guo S, Jiang Y. The switch I region of Rheb is critical for 
its interaction with FKBP38. J Biol Chem. 2008;283:25963-70. 
60 
 
55. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant 
D, et al. Two TOR complexes, only one of which is rapamycin sensitive, 
have distinct roles in cell growth control. Mol Cell. 2002;10:457-68. 
56. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and 
metabolism. Cell. 2006;124:471-84. 
57. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, 
Alperovich G, et al. Mammalian target of rapamycin pathway blockade 
slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 
2006;17:1395-404. 
58. Chen JK, Chen J, Thomas G, Kozma SC, Harris RC. S6 kinase 1 
knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. 
Am J Physiol Renal Physiol. 2009;297:F585-93. 
59. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. 
Inhibition of mTOR signaling with rapamycin attenuates renal 
hypertrophy in the early diabetic mice. Biochem Biophys Res Commun. 
2006;340:296-301. 
60. Wolf G. Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl. 
2000;77:S59-66. 
61. Wolf G, Schroeder R, Ziyadeh FN, Thaiss F, Zahner G, Stahl RA. High 
glucose stimulates expression of p27Kip1 in cultured mouse mesangial 
cells: relationship to hypertrophy. Am J Physiol. 1997;273:F348-56. 
62. Wolf G, Wenzel U, Ziyadeh FN, Stahl RA. Angiotensin converting-
enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 
expression in diabetic BBdp rats. Diabetologia. 1999;42:1425-32. 
63. Kuan CJ, al-Douahji M, Shankland SJ. The cyclin kinase inhibitor 
p21WAF1, CIP1 is increased in experimental diabetic nephropathy: 
potential role in glomerular hypertrophy. J Am Soc Nephrol. 1998;9:986-
93. 
64. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular 
podocyte. Physiol Rev. 2003;83:253-307. 
65. Chuang TD, Guh JY, Chiou SJ, Chen HC, Huang JS, Yang YL, et al. 
Phosphoinositide 3-kinase is required for high glucose-induced 
hypertrophy and p21WAF1 expression in LLC-PK1 cells. Kidney Int. 
2007;71:867-74. 
66. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, 
61 
 
Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 
phosphorylation. Mol Cell. 2008;30:701-11. 
67. Juengel E, Engler J, Natsheh I, Jones J, Mickuckyte A, Hudak L, et al. 
Combining the receptor tyrosine kinase inhibitor AEE788 and the 
mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly 
inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer. 
2009;9:161. 
68. Paternot S, Roger PP. Combined inhibition of MEK and mammalian 
target of rapamycin abolishes phosphorylation of cyclin-dependent 
kinase 4 in glioblastoma cell lines and prevents their proliferation. 
Cancer Res. 2009;69:4577-81. 
69. Matsumoto E, Hatanaka M, Bohgaki M, Maeda S. PKC pathway and 
ERK/MAPK pathway are required for induction of cyclin D1 and 
p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced 
differentiation of myeloleukemia cells. Kobe J Med Sci. 2006;52:181-94. 
70. Amzallag N, Passer BJ, Allanic D, Segura E, Thery C, Goud B, et al. 
TSAP6 facilitates the secretion of translationally controlled tumor 
protein/histamine-releasing factor via a nonclassical pathway. J Biol 
Chem. 2004;279:46104-12. 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
ABSTRACT (in Korean) 
 
 
당뇨 조건하에서 translationally controlled tumor protein이  
족세포의 비후에 미치는 영향 
 
<지도교수 강 신 욱> 
연세대학교 대학원 의학과 
김 동 기 
 
배경: 세포 비후 과정은 세포 주기 조절 단백 중 주로 cyclin-dependent 
kinase 억제제 (CKIs)의 발현 증가와 밀접하게 연관되어 있다. 최근의 
연구에 의하면, CKIs 이외에도 mammalian target of rapamycin (mTOR)와 같은 
mRNA 전사를 조절하는 세포 신호 전달계의 활성화도 세포 비후를 
유발시키는 것으로 보고되고 있다. Translationally controlled tumor protein 
(TCTP)은 대부분의 진핵세포에 잘 보존된 상태 (conserve)로 존재하며, 
mRNA 전사 조절 과정을 통하여 세포 증식 및 비후 등 다양한 세포 내 
현상과 관련이 있을 것으로 생각되어 왔다. 당뇨병성 신병증의 병리학적 
특징 중 하나가 사구체 비후이기 때문에, TCTP와 당뇨병성 신병증의 발생 
사이에 연관이 있을 가능성이 있으나, 이에 대한 연구는 전무한 실정이다. 
이에 본 연구자는 고포도당으로 자극한 족세포와 실험적 당뇨 사구체에서 
TCTP의 발현 변화를 관찰하였으며, 당뇨 조건 하에서 TCTP가 족세포의 
비후에 미치는 영향을 규명하고자 하였다. 
방법: 생체 내 실험으로는 불멸 생쥐 족세포를 정상 포도당군 (5.6 mM), 
정상 포도당+만니톨군 (24.4 mM), 정상 포도당+안지오텐신 II 군 (10-6 M), 
고포도당군 (30 mM), 그리고 고포도당+L-158,809 처치군 (10-7 M)으로 
나누어 배양하였으며, TCTP 발현 억제를 위하여 TCTP shRNA를 포함한 
lentivirus로 전처치한 실험도 시행하였다. 생체 내 실험으로는 32마리의 
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C57BL/6 생쥐를 사용하였으며, 16마리는 대조군, 그리고 16마리는 
streptozotocin으로 당뇨를 유발시킨 당뇨군으로 나누었고, 각 군에서 
8마리씩은 TCTP shRNA를 포함한 lentivirus로 처치하였다. 배양 족세포 및 
분리한 사구체 내 TCTP mRNA의 발현은 real-time PCR으로, TCTP, phospho-
4EBP1, 4EBP1, phospho-p70S6K, p70S6K, p27, p21, 그리고 β-actin의 단백 
발현은 Western blot을 이용하여 분석하였다. 사구체 내 TCTP 단백의 발현 
위치는 synaptopodin과 TCTP을 이용한 이중 면역형광염색으로 관찰하였다. 
족세포 비후는 단백량/세포 수 및 유세포 분석으로, 그리고 사구체 비후는 
morphometry를 이용하여 확인하였다. 
결과: TCTP mRNA 및 단백의 발현은 정상 포도당군에 비하여 고포도당에서 
의미있게 증가되었으며, 고포도당군에서의 TCTP 발현 증가는 L-158,809에 
의하여 의의있게 억제되었다. 안지오텐신 II 역시 배양 족세포에서 TCTP의 
발현을 유의하게 증가시켰다. 사구체 내 TCTP의 발현도 대조군에 비하여 
당뇨군에서 의미있게 증가되었으며, 이중 면역형광염색상 당뇨 사구체 내 
TCTP의 발현 증가는 주로 족세포의 발현 증가에 기인함을 확인하였다. 
생체 내 및 생체 외 실험상 TCTP shRNA를 포함한 lentivirus로 처치한 경우 
당뇨 조건 하에서 phospho-4EBP1, phospho-p70S6K, 그리고 p27의 단백 발현 
증가뿐만 아니라 족세포 및 사구체 비후가 유의하게 억제되었다. 
결론: 당뇨 조건 하에서 족세포 내 TCTP의 발현이 증가되었으며, TCTP 
억제를 통하여 당뇨 조건 하에서 세포비후와 관련된 4EBP1과 p70S6K의 
활성화 및 CKIs의 발현 증가와 함께 족세포 비후가 의미있게 억제되었다. 
이상의 결과를 종합해 볼 때, TCTP는 mRNA의 전사 조절과 세포 주기의 
진행 억제를 통하여 당뇨 조건 하에서의 족세포 비후에 관여할 것으로 
생각된다. 
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